

U.S.S.N. 08/823,999  
Filed March 25, 1997  
SUBSTITUTE APPEAL BRIEF

### Appendix: Claims as pending

1. (Previously presented) A method of inhibiting or reducing stenosis arising from coronary artery bypass surgery, peripheral bypass surgery, or transplantation of cells, tissue or organs or restenosis of a blood vessel following injury to vascular tissue in a region of the blood vessel of a patient in need of treatment thereof, comprising:

administering systemically or at the site of the injury a pharmaceutically acceptable composition comprising a compound which specifically inhibits or reduces leukocyte integrin-mediated adhesion or function,

wherein the integrin is selected from the group consisting of Mac-1 (CD11b/CD18), LFA-1 (CD11a/CD18), p150,95 (CD11c/CD18), and CD11d/CD18,

wherein the compound is selected from the group consisting of antibodies and antibody fragments that are immunoreactive with the integrins or integrin-ligands and which block the interaction of the integrins or integrin-ligands with vascular cells; molecules which inhibit expression of the integrins or integrin-ligands, and peptides and peptidomimetics derived from the integrins or integrin-ligands which block the interaction of the integrins or integrin-ligands with vascular cells or tissues,

in an amount effective to inhibit or reduce stenosis arising from coronary artery bypass surgery, peripheral bypass surgery, or transplantation of cells, tissue or organs or restenosis of a blood vessel following injury to vascular tissue.

2. (Original) The method of claim 1 wherein the leukocytes are monocytes or granulocytes.

U.S.S.N. 08/823,999  
Filed March 25, 1997  
SUBSTITUTE APPEAL BRIEF

3. (Previously presented) The method of claim 1 wherein the injury arises from angioplasty, atherectomy, or endovascular stenting.

4. (Original) The method of claim 1 wherein the composition is in a form selected from the group consisting of solutions, gels, foams, suspensions, polymeric carriers, and liposomes.

5. (Previously presented) The method of claim 1 wherein the integrin is selected from the group consisting of LFA-1 (CD11a/CD18), p150,95 (CD11c/CD18), and CD11d/CD18.

6. (Previously presented) A method of inhibiting or reducing stenosis arising from , coronary artery bypass surgery, peripheral bypass surgery, or transplantation of cells, tissue or organs or restenosis of a blood vessel following injury to vascular tissue in a region of the blood vessel of a patient in need of treatment thereof, comprising:

administering systemically or at the site of the injury a pharmaceutically acceptable composition comprising a compound which specifically inhibits or reduces leukocyte integrin-mediated adhesion or function,

wherein the integrin is Mac-1 (CD11b/CD18),

wherein the compound is selected from the group consisting of antibodies and antibody fragments that are immunoreactive with the integrins or integrin-ligands and which block the interaction of the integrins or integrin-ligands with vascular cells; molecules which inhibit expression of the integrins or integrin-ligands, and peptides and peptidomimetics derived from the integrins or integrin-ligands which block the interaction of the integrins or integrin-ligands

U.S.S.N. 08/823,999  
Filed March 25, 1997  
SUBSTITUTE APPEAL BRIEF

with vascular cells or tissues,

in an amount effective to inhibit or reduce stenosis arising from coronary artery bypass surgery, peripheral bypass surgery, or transplantation of cells, tissue or organs or restenosis of a blood vessel following injury to vascular tissue.

7. (Withdrawn) The method of claim 5 wherein the ligand is selected from the group consisting of ICAM-1, fibrin(ogen), C3bi, and factor X.

8. (Previously presented) The method of claim 1 wherein the compound is selected from the group consisting of antibodies and antibody fragments that are immunoreactive with the integrins or their ligands and which block the interaction of the integrins or their ligands with vascular cells.

9. (Withdrawn) The method of claim 5 wherein the integrin is LFA-1 and the ligand is selected from the group consisting of ICAM-1, ICAM-2, ICAM-3.

10. (Previously presented) The method of claim 6 wherein the compound is an antibody or antibody fragment immunoreactive with Mac-1 (CD11b/CD18).

11. (Original) The method of claim 1 wherein the compound is administered to a patient in need thereof prior to vascular intervention.

12. (Original) The method of claim 11 wherein the compound is administered to a the patient prior to and after vascular intervention, until healing has occurred.

13. to 17. (Cancelled)